Jefferies Reaffirms Their Buy Rating on Merck & Company (MRK)
In a report released on January 21, Akash Tewari from Jefferies reiterated a Buy rating on Merck & Company (MRK – Research Report). The ...
Kennedy Jr. to keep vaccine suit stake if confirmed as health chief, FT says
Robert Kennedy Jr. will keep his share of any windfall from litigation against Merck (MRK) even if he becomes Donald Trump’s top U.S. health ...
24/7 Wall St. on MSN15h
4 Mega-Cap High-Yield Dividend Giants Look Like Huge 2025 Winners
These four mega-cap dividend stocks offer the best total return potential for 2025. They are rated Buy at top Wall Street ...
RJK Jr.'s Involvement In Merck Lawsuit Faces Scrutiny Ahead Of Senate Hearing
Robert F. Kennedy Jr., President Donald Trump‘s nominee for Health and Human Services Secretary, is facing scrutiny over his decision to retain financial interests in ongoing litigation against Merck ...
Agri-Pulse2h
House Ag releases subcommittee assignments
House Ag Committee Chair Glenn "GT" Thompson speaks to the crowd in a Holstein print bowtie at the ag inaugural ball Jan. 20 The House Agriculture Committee on Thursday released its subcommittee ...
Merck KGaA says high asset prices call for prudent M&A approach
The CEO of Germany's Merck KGaA said a recovery in sales growth at its existing business means it can take a cautious ...
AstraZeneca's Growth Potential: 6 Reasons For A Buy Rating
AstraZeneca is a leader in cancer treatments with FDA-approved drugs. Read why AZN stock is still a 'Buy' and why the company’s future looks bright.
Jim Cramer Discusses These 18 Stocks & President Trump’s $500 Billion AI Plan
In this piece, we will look at the stocks Jim Cramer recently discussed.
Arcutis Biotherapeutics: After Outstanding 2024, Shares May Face Cooling Off Period
Financial writer analysis of Arcutis Biotherapeutics, Inc. stock surge and potential growth, FDA approvals, and partnerships in 2025. Click for this ARQT update.